Circulating Nucleic Acids in Early Diagnosis, Prognosis and Treatment Monitoring: An Introduction

476 Pages·2015·6.37 MB·English

by  Peter B. Gahan (eds.)

Advances in Predictive, Preventive and Personalised Medicine
Series Editor: Olga Golubnitschaja
Peter B. Gahan Editor
Circulating Nucleic
Acids in Early
Diagnosis, Prognosis
and Treatment
Monitoring
An Introduction
Circulating Nucleic Acids in Early Diagnosis,
Prognosis and Treatment Monitoring
Advances in Predictive, Preventive and Personalised
Medicine
Volume 5
Series Editor:
Olga Golubnitschaja
Managing Editor:
Kristina Yeghiazaryan
Forfurthervolumes:
http://www.springer.com/series/10051
Peter B. Gahan
Editor
Circulating Nucleic Acids in
Early Diagnosis, Prognosis
and Treatment Monitoring
An Introduction
Editor
PeterB.Gahan
Anatomy&HumanSciences
King’sCollegeLondon
London
UnitedKingdom
ISSN2211-3495 ISSN2211-3509(electronic)
ISBN978-94-017-9167-0 ISBN978-94-017-9168-7(eBook)
DOI10.1007/978-94-017-9168-7
SpringerDordrechtHeidelbergNewYorkLondon
LibraryofCongressControlNumber:2014954083
©SpringerScience+BusinessMediaDordrecht2015
Thisworkissubjecttocopyright.AllrightsarereservedbythePublisher,whetherthewholeorpart
of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations,
recitation,broadcasting,reproductiononmicrofilmsorinanyotherphysicalway,andtransmissionor
informationstorageandretrieval,electronicadaptation,computersoftware,orbysimilarordissimilar
methodologynowknownorhereafterdeveloped.Exemptedfromthislegalreservationarebriefexcerpts
inconnectionwithreviewsorscholarlyanalysisormaterialsuppliedspecificallyforthepurposeofbeing
enteredandexecutedonacomputersystem,forexclusiveusebythepurchaserofthework.Duplication
ofthispublicationorpartsthereofispermittedonlyundertheprovisionsoftheCopyrightLawofthe
Publisher’s location, in its current version, and permission for use must always be obtained from
Springer.PermissionsforusemaybeobtainedthroughRightsLinkattheCopyrightClearanceCenter.
ViolationsareliabletoprosecutionundertherespectiveCopyrightLaw.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this
publicationdoesnotimply,evenintheabsenceofaspecificstatement,thatsuchnamesareexempt
fromtherelevantprotectivelawsandregulationsandthereforefreeforgeneraluse.
While the advice and information in this book are believed to be true and accurate at the date of
publication,neithertheauthorsnortheeditorsnorthepublishercanacceptanylegalresponsibilityfor
anyerrorsoromissionsthatmaybemade.Thepublishermakesnowarranty,expressorimplied,with
respecttothematerialcontainedherein.
Printedonacid-freepaper
SpringerispartofSpringerScience+BusinessMedia(www.springer.com)
TO
MAURICE STROUN
who overcame scientific and political
resistance to lay the foundations leading to
the current studies on circulating nucleic
acids.
ThiSisaFMBlankPage
What This Book Series Is About…
Current Healthcare: What Is Behind the Issue?
Formanyacuteandchronicdisorders,thecurrenthealthcareoutcomesareconsid-
ered as being inadequate: global figures cry for preventive measures and
personalisedtreatments.Infact,severechronicpathologiessuchascardiovascular
disorders, diabetes and cancer are treated after onset of the disease, frequently at
near end-stages. Pessimistic prognosis considers pandemic scenario for type 2
diabetes mellitus, neurodegenerative disorders and some types of cancer over the
next 10–20 years followed by the economic disaster of healthcare systems in a
globalscale.
Advanced Healthcare Tailored to the Person: What Is
Beyond the Issue?
Advancedhealthcarepromotestheparadigmchangefromdelayedinterventionalto
predictivemedicinetailoredtotheperson,fromreactivetopreventivemedicineand
from disease to wellness. The innovative predictive, preventive and personalised
medicine (PPPM) is emerging as the focal point of efforts in healthcare aimed at
curbing the prevalence of both communicable and non-communicable diseases
such asdiabetes, cardiovascular diseases,chronicrespiratory diseases, cancer and
dentalpathologies.Thecost-effectivemanagementofdiseasesandthecriticalrole
of PPPM in modernisation of healthcare have been acknowledged as priorities by
global andregionalorganisations andhealth-related institutionssuch astheOrga-
nisation of United Nations, the European Union and the National Institutes of
Health.
vii
viii WhatThisBookSeriesIsAbout…
Why Integrative Medical Approach by PPPM as the
Medicine of the Future?
PPPM is the new integrative concept in healthcare sector that enables to predict
individualpredispositionbeforeonsetofthedisease,toprovidetargetedpreventive
measuresandcreatepersonalisedtreatmentalgorithmstailored tothe person. The
expectedoutcomesareconducivetomoreeffectivepopulationscreening,preven-
tionearlyinchildhood,identificationofpersonsatrisk,stratificationofpatientsfor
theoptimaltherapyplanning,andpredictionandreductionofadversedrug-drugor
drug-disease interactions relying on emerging technologies, such as pharmaco-
genetics, pathology-specific molecular patterns, sub-cellular imaging, disease
modelling, individual patient profiles, etc. Integrative approach by PPPM is con-
sideredasthemedicineofthefuture.Beingattheforefrontoftheglobalefforts,the
European Association for Predictive, Preventive and Personalised Medicine
(EPMA, http://www.epmanet.eu/) promotes the integrative concept of PPPM
amonghealthcarestakeholders,governmentalinstitutions,educators,fundingbod-
ies,patientorganisationsandinthepublicdomain.
CurrentBookSeries,publishedbySpringerincollaborationwithEPMA,over-
viewmultidisciplinaryaspectsofadvancedbio-medicalapproachesandinnovative
technologies.Integrationofindividualprofessionalgroupsintotheoverallconcept
of PPPM is a particular advantage of this book series. Expert recommendations
focusonthecost-effectivemanagementtailoredtothepersoninhealthanddisease.
Innovativestrategiesareconsideredforstandardisationofhealthcareservices.New
guidelines are proposed for medical ethics, treatment of rare diseases, innovative
approaches to early and predictive diagnostics, patient stratification and targeted
prevention in healthy individuals, persons at risk, individual patient groups, sub-
populations,institutions,healthcareeconomyandmarketing.
WhatThisBookSeriesIsAbout… ix
Prof.Dr.OlgaGolubnitschaja
BookSeriesEditor
Dr.Golubnitschaja,DepartmentofRadiology,MedicalFacultyoftheUniversity
in Bonn, Germany, has studied journalism, biotechnology and medicine and has
beenawardedfellowshipsforbiomedicalresearchinPaediatricsandNeurosciences
(MedicalCentresinAustria,Russia,UK,Germany,theNetherlands,andSwitzer-
land). She is well-cited in the research fields of “gene hunting” and “subtractive
hybridisation”appliedtopredictiveprenatalandpostnataldiagnosticspublishedas
O. Labudova in years 1990–2000. Dr. Golubnitschaja is an expert in molecular
diagnosticsactivelypublishinginthefieldsofophthalmicdiseases,neurodegener-
ative pathologies, cancer, cardiovascular disease, Diabetes mellitus, hyperhomo-
cysteinemia, etc. She is the cofounder of the theory of individual patient profiles,
author of fundamental works in systems medicine (holistic approach considering
molecularpatternsatepi/genomic,transcriptionalandpost/translationallevels).Dr.
Golubnitschaja holds appointments, at the rank of Professor, at several European
Universities and in International Programmes for Personalised Medicine, and is
authorofmorethan300internationalpublicationsinthefield.Herawardsinclude:
NationalandInternationalFellowshipoftheAlexandervonHumboldt-Foundation,
Highest Prize in Medicine and Eiselsberg-Prize in Austria. She is Secretary-Gen-
eral of the “European Association for Predictive, Preventive and Personalised
Medicine”(EPMAinBrussels,www.epmanet.eu),Editor-in-ChiefofTheEPMA-
Journal (BioMed Central, London); Book Editor of Predictive Diagnostics and
Personalized Treatment: Dream or Reality, Nova Science Publishers, New York
2009; Book Co-editor Personalisierte Medizin, Health Academy, Dresden 2010;
Book Series Editor of Advances in Predictive, Preventive and Personalised Med-
icine, Springer 2012; European Representative in the EDR-Network at the NIH/
NCI, http://edrn.nci.nih.gov/; Advisor and Evaluator of projects dedicated to
personalisedmedicineattheEU-CommissioninBrussels,NIH/NCI,Washington,
DC,USA,andFoundationsandNationalMinistriesofHealthinseveral countries
worldwide.